Shreyas Kalantri, Hematology and Oncology Chief Fellow at the University of Louisville, shared a post on X:
“ASH Plenary Spotlight
PARADIGM phase 2 trial compares azacitidine plus venetoclax (aza-ven) with intensive induction chemotherapy (IC) in fit, IC-eligible adults with newly diagnosed AML.
Key findings (n=172):
- Higher overall response with aza-ven vs IC (88 percent vs 62 percent; P<0.001)
- Higher composite complete remission rate (81 percent vs 55 percent; P<0.001)
- 1-year EFS 53 percent with aza-ven vs 39 percent with IC (HR 0.61; P=0.017)
- 30- and 60-day mortality both 0 percent with aza-ven, vs 3.5 percent and 4.7 percent with IC
- Better early QOL, symptom burden, and depression scores with aza-ven
- Fewer ICU admissions (0 vs 9.8 percent; P=0.003)
- Fewer inpatient days during the index hospitalization and over 6 months
Conclusion: Aza-ven met the primary endpoint, showing improved EFS, higher responses, better tolerability, and improved QOL compared with IC in younger, fit AML patients. OS continues to mature.”
More posts featuring Shreyas Kalantri.
